Business
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris\nMONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.1 Knight obtained the Canadian rights to WYNZORA® through its June 2025 acquisition of the assets of Paladin Pharma Inc. (“Paladin”). In November 2024, Paladin had entered into a license agreement with MC2 Therapeutics (\"MC2\") to commercialize WYNZORA® in Canada. MC2 is a private pharmaceutical company based in Hørsholm, Denmark and in Guildford, United Kingdom. “By uniting two proven mechanisms in a once-daily cream, WYNZORA® addresses the twin challenges of adherence and symptom control. Health Canada’s approval expands the treatment landscape with an evidence-based, practical therapy that can improve quality of life without adding monitoring burden,” said Dr. Charles Lynde MD, Dermatologist at The Lynde Institute for Dermatology in Markham, Ontario. “We are proud to introduce WYNZORA® to patients in Canada, offering an innovative treatment option for psoriasis vulgaris that combines efficacy with convenience. This launch underscores our commitment to improving quality of life for Canadian patients, while continuing our broader mission to bring innovative therapies to all markets we serve,” said Samira Sakhia, President and CEO, Knight Therapeutics Inc. About WYNZORA® WYNZORA® is a cream-based fixed dose combination of CAL and BDP for topical treatment of psoriasis vulgaris developed by MC2. WYNZORA® has a broad mode of action by targeting keratinocyte proliferation and differentiation and inhibiting expression of pro-inflammatory hallmark cytokines such as IL-23, IL-17A/F and TNF-α. In WYNZORA®, the combination of CAL and BDP has greater anti-inflammatory and anti-proliferative effects than either component alone...